Clinical and pathological features of kidney transplant patients with concurrent polyomavirus nephropathy and rejection-associated endarteritis

Table 2 Clinical information

	Baseline Cr	Serum Cr at index biopsy (mg/dL)	BKV DNA copies/mL at index biopsy		Maintenance IS	Change of IS after diagnosis of PVN		Antirejection therapy				Antiviral		Creatinine trend (mo; mg/dL)				BK viremia trend (mo; × 103 copies/mL)
			Serum (× 103)	Urine (× 106)		Disc. MMF	Reduced Tacrolimus	Steroids	IVIG	Rapamycin	Thymoglobulin	Arava	Cidofovir	1	3	6	12	3	12	Time to clear
1	1.2	3.4	33002	> 13002	MTP	Yes1	Yes1	Yes	No	No	No	Yes	Yes	1	2	3	3.933	Pos4	Pos4	Not cleared4
2	1.1	1.8	0	1.3	MTP	Yes1	Yes1	No	Yes	No	No	No	Yes	1	3	2	2	0	0	NA
3	1.3	6.2	ND	ND	MTP	Yes1	No	ND	ND	ND	ND	ND	ND	4	ND	3	GL	ND	ND	ND
4	1.8	1.9	0	ND	MTP	Yes1	No	Yes	No	No	Yes	Yes	No	2	3	4	GL	0	0	NA
5	1.8	2.2	2102	> 13002	MTP	Yes	No	No	Yes	No	No	Yes	No	2	2	2	2	< 2.5	0	9
6	1.7	1.7	7	> 25	MTP	Yes	No	Yes	No	No	Yes	Yes	No	2	2	2	1	0	0	2
7	1.2	1.7	1342	17002	STP	NA	Yes	No	No	No	No	Yes	No	2	2	2	1	0.6	0	9

¹Change occurred prior to index biopsy;

²BK viral load performed at outside institution with different reference ranges;

³Subsequent graft loss at 483 d;

⁴Positive, exact viral titers not available. BKV: BK virus; IS: Immunosuppression; PVN: Polyomavirus nephropathy; MMF: Mycophenolate mofetil; IVIG: Intravenous immunoglobulin; MTP: Mycophenolate mofetil, tacrolimus and prednisone; NA: Not applicable; ND: Not determined; GL: Graft loss; STP: Sirolimus, tacrolimus and prednisone.